GSK, Ranbaxy And Others Expected To Face Questioning From India Regulator On U.S. FDA Drug List
This article was originally published in PharmAsia News
Executive Summary
India's drug regulator is expected to ask makers in the country to supply data on adverse reactions to drugs. The new concern was sparked by the U.S. FDA listing 20 drugs with such problems, at least six of them sold in India. The six are heparin, ivermectin, nitroglycerine, octreotide acetate, quetiapine and warfarin. The drugs controller general of India is expected to seek data from Cipla, Lupin, Ranbaxy Laboratories, Sun Pharmaceuticals and Torrent Pharmaceuticals, all of India, as well as U.K.-based GlaxoSmithkline Pharmaceuticals, makers or one or more of the drugs. D.G. Shah, the Indian Pharmaceutical Alliance's secretary general, said that would be normal practice for the DCGI. (Click here for more